Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Operating Leases of $7.2 million for Q1 2026, down 29.59% year-over-year from $10.3 million in Q1 2025, and down 8.31% quarter-over-quarter from $7.9 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Operating Leases for 4 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 29.59% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (down 29.59% YoY), while the FY2025 annual figure was $7.9 million, down 25.42% from the prior year.
- Operating Leases fell to $7.2 million in Q1 2026 per ARTV's latest filing, from $7.9 million in the prior quarter.
- Across five years, Operating Leases topped out at $15.5 million in Q2 2024 and bottomed at $7.2 million in Q1 2026.
- Historically, Operating Leases has averaged $10.5 million across 4 years, with a median of $10.3 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Leases fell 20.62% — and 2025, when it plunged 38.35%.
- Artiva Biotherapeutics' Operating Leases stood at $13.3 million in 2023, then retreated by 20.62% to $10.6 million in 2024, then slipped by 25.42% to $7.9 million in 2025, then retreated by 8.31% to $7.2 million in 2026.
- Business Quant data shows ARTV's Operating Leases at $7.2 million in Q1 2026, $7.9 million in Q4 2025, and $8.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.55 Mn |
| Mar 31, 2026 | 7.23 Mn |
| Dec 31, 2025 | 7.88 Mn |
| Sep 30, 2025 | 8.52 Mn |
| Jun 30, 2025 | 9.58 Mn |
| Mar 31, 2025 | 10.27 Mn |
| Dec 31, 2024 | 10.57 Mn |
| Sep 30, 2024 | 11.16 Mn |
| Jun 30, 2024 | 15.54 Mn |
| Dec 31, 2023 | 13.32 Mn |